Lawrence Sher

7.8k total citations · 2 hit papers
49 papers, 1.7k citations indexed

About

Lawrence Sher is a scholar working on Physiology, Immunology and Allergy and Dermatology. According to data from OpenAlex, Lawrence Sher has authored 49 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Physiology, 16 papers in Immunology and Allergy and 12 papers in Dermatology. Recurrent topics in Lawrence Sher's work include Asthma and respiratory diseases (24 papers), Allergic Rhinitis and Sensitization (14 papers) and Dermatology and Skin Diseases (11 papers). Lawrence Sher is often cited by papers focused on Asthma and respiratory diseases (24 papers), Allergic Rhinitis and Sensitization (14 papers) and Dermatology and Skin Diseases (11 papers). Lawrence Sher collaborates with scholars based in United States, France and Germany. Lawrence Sher's co-authors include Neil M.H. Graham, Gianluca Pirozzi, Sheldon L. Spector, Sally E. Wenzel, Jennifer D. Hamilton, Linda Ford, Ross E. Rocklin, Lin Wang, Neil Stahl and Franck Skobieranda and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Lawrence Sher

48 papers receiving 1.6k citations

Hit Papers

Dupilumab in Persistent Asthma with Elevated Eosinophil L... 2013 2026 2017 2021 2013 2025 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
    2013 951 citations Sally E. Wenzel, Linda Ford et al. New England Journal of Medicine profile →
  2. A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults
    2025 18 citations Mieke Soens, Jintanat Ananworanich et al. Vaccine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lawrence Sher United States 15 1.0k 578 491 397 285 49 1.7k
Delphine Gras France 23 867 0.9× 625 1.1× 280 0.6× 561 1.4× 82 0.3× 54 2.0k
Gary N. Gross United States 24 1.2k 1.2× 1.1k 1.8× 465 0.9× 179 0.5× 117 0.4× 66 2.0k
JC Virchow Germany 16 1.0k 1.0× 586 1.0× 582 1.2× 256 0.6× 162 0.6× 33 1.4k
Nicholas S. Jones United Kingdom 25 488 0.5× 276 0.5× 436 0.9× 120 0.3× 121 0.4× 69 2.0k
Kerstin Wanke Switzerland 11 368 0.4× 126 0.2× 239 0.5× 261 0.7× 87 0.3× 14 1.0k
Rami J. Salib United Kingdom 19 335 0.3× 198 0.3× 322 0.7× 64 0.2× 44 0.2× 64 1.0k
Dae Jin Song South Korea 21 425 0.4× 272 0.5× 151 0.3× 212 0.5× 64 0.2× 72 1.1k
José Manuel Zubeldia Spain 23 383 0.4× 115 0.2× 616 1.3× 321 0.8× 244 0.9× 77 1.4k
D.А. Kudlаy Russia 21 227 0.2× 127 0.2× 140 0.3× 292 0.7× 116 0.4× 287 1.6k
Julie Bérubé Canada 20 195 0.2× 270 0.5× 79 0.2× 702 1.8× 38 0.1× 41 1.5k

Countries citing papers authored by Lawrence Sher

Since Specialization
Citations

This map shows the geographic impact of Lawrence Sher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Sher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Sher more than expected).

Fields of papers citing papers by Lawrence Sher

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Sher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Sher. The network helps show where Lawrence Sher may publish in the future.

Co-authorship network of co-authors of Lawrence Sher

This figure shows the co-authorship network connecting the top 25 collaborators of Lawrence Sher. A scholar is included among the top collaborators of Lawrence Sher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lawrence Sher. Lawrence Sher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Soens, Mieke, Jintanat Ananworanich, Kathryn Jean Lucas, et al.. (2025). A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults. Vaccine. 50. 126847–126847. 18 indexed citations breakdown →
2.
Corren, Jonathan, Nicola A. Hanania, William W. Busse, et al.. (2023). Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization. Clinical & Experimental Allergy. 53(10). 1020–1030. 3 indexed citations
3.
Sher, Lawrence, Giovanni Passalacqua, Camille Taillé, et al.. (2022). The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma. Annals of Allergy Asthma & Immunology. 130(3). 298–304. 5 indexed citations
4.
Sher, Lawrence, Michael E. Wechsler, Klaus F. Rabe, et al.. (2022). Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma. CHEST Journal. 162(1). 46–55. 24 indexed citations
5.
Bansal, Ashish, Eric L. Simpson, Amy S. Paller, et al.. (2021). Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology. 22(1). 101–115. 34 indexed citations
6.
Castro, Mario, Edward Kerwin, David Miller, et al.. (2021). Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2). EClinicalMedicine. 35. 100847–100847. 27 indexed citations
7.
Beck, Lisa A., Diamant Thaçi, Mette Deleuran, et al.. (2020). Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology. 21(4). 567–577. 93 indexed citations
8.
Sher, Lawrence, Robert Wolfe, Santiago Quirce, et al.. (2020). DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA. CHEST Journal. 158(4). A1752–A1754. 1 indexed citations
9.
10.
11.
Larenas‐Linnemann, Désirée, et al.. (2016). American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. Allergy and Asthma Proceedings. 37(5). 112–122. 12 indexed citations
12.
Wenzel, Sally E., Robert W. Hopkins, Michael D. Saunders, et al.. (2014). Safety and Efficacy Of ARRY-502, a Potent, Selective, Oral CRTh2 Antagonist, In Patients With Mild To Moderate Th2-Driven Asthma. Journal of Allergy and Clinical Immunology. 133(2). AB4–AB4. 14 indexed citations
13.
Wenzel, Sally E., Linda Ford, David S. Pearlman, et al.. (2013). Dupilumab in Persistent Asthma with Elevated Eosinophil Levels. New England Journal of Medicine. 368(26). 2455–2466. 951 indexed citations breakdown →
14.
Rubino, Christopher M., Paul G. Ambrose, Brenda Cirincione, et al.. (2007). Pharmacokinetics and pharmacodynamics of gatifloxacin in children with recurrent otitis media: application of sparse sampling in clinical development. Diagnostic Microbiology and Infectious Disease. 59(1). 67–74. 4 indexed citations
15.
Sher, Lawrence, Adriano Arguedas, Michael E. Pichichero, et al.. (2005). Randomized, Investigator-Blinded, Multicenter, Comparative Study of Gatifloxacin Versus Amoxicillin/Clavulanate in Recurrent Otitis Media and Acute Otitis Media Treatment Failure in Children. The Pediatric Infectious Disease Journal. 24(4). 301–308. 19 indexed citations
16.
17.
Sher, Lawrence, et al.. (2002). Community‐Based Treatment of Acute Uncomplicated Bacterial Rhinosinusitis with Gatifloxacin. Otolaryngology. 127(3). 182–189. 8 indexed citations
18.
Sher, Lawrence. (1993). The oscillating-mirror technique for realizing true 3D. Princeton University Press eBooks. 196–213. 2 indexed citations
19.
Chylack, L.T., et al.. (1988). Standardization and analysis of digitized photographic data in the longitudinal documentation of cataractous growth. Current Eye Research. 7(3). 223–235. 4 indexed citations
20.
Sher, Lawrence. (1988). Spacegraph, A True 3-D Pc Peripheral. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 902. 10–10. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Delphine Gras Breakdown of academic impact, for papers by Gary N. Gross Breakdown of academic impact, for papers by JC Virchow Breakdown of academic impact, for papers by Nicholas S. Jones Breakdown of academic impact, for papers by Kerstin Wanke Breakdown of academic impact, for papers by Rami J. Salib Breakdown of academic impact, for papers by Dae Jin Song Breakdown of academic impact, for papers by José Manuel Zubeldia Breakdown of academic impact, for papers by D.А. Kudlаy Breakdown of academic impact, for papers by Julie Bérubé
Rankless by CCL
2026